Skip to main content
Midas Edge

GUIDED THERAPEUTICS INC

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

GTHPStored price and day change unavailable
See the whole filing, with its images and exhibits
Contents

Item 1. Financial Statements

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
March 31,December 31,
20242023
ASSETS
Current Assets:
Cash and cash equivalents$445$591
Accounts receivable, net of allowance for credit losses of $2 at March 31, 2024 and December 31, 202377
Inventory, net of reserves of $818 at March 31, 2024 and December 31, 2023632632
Other current assets156163
Total current assets1,2401,393
Non-Current Assets:
Property and equipment, net3032
Operating lease right-of-use asset, net of amortization207227
Other assets1717
Total non-current assets254276
TOTAL ASSETS$1,494$1,669
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable$1,924$1,991
Accounts payable, related parties3032
Accrued liabilities780970
Deferred revenue748424
Current portion of lease liability9591
Current portion of long-term debt, related parties51239
Short-term notes payable2459
Short-term convertible notes payable1,2291,203
Total current liabilities5,3424,809
Long-Term Liabilities
Long-term lease liability130155
Long-term debt, related parties34511
Total long-term liabilities164666
Total liabilities5,5065,475
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS’ DEFICIT:
Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, 0.3 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $286 at March 31, 2024 and December 31, 2023.105105
Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 1.0 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $1,049 at March 31, 2024 and December 31, 2023.170170
Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, 2.7 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $2,700 at March 31, 2024 and December 31, 2023.439439
Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.4 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $438 at March 31, 2024 and December 31, 2023.159159
Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $883 at March 31, 2024 and December 31, 2023.834834
Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.1 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $1,006 at March 31, 2024 and December 31, 2023.838838
Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of March 31, 2024 and December 31, 2023. Liquidation preference of $520 at March 31, 2024 and December 31, 2023.475475
Common stock, $0.001 par value; 500,000 shares authorized, 55,614 and 54,105 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.3,4413,441
Additional paid-in capital141,218140,983
Treasury stock at cost(132)(132)
Accumulated deficit(151,559)(151,118)
Total stockholders’ deficit(4,012)(3,806)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT$1,494$1,669
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.